

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 738 146 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
02.05.2003 Bulletin 2003/18

(51) Int Cl.7: **A61K 31/195**, A61P 3/02,
A61P 1/16

(21) Application number: **95904697.0**

(86) International application number:
PCT/NL95/00015

(22) Date of filing: **11.01.1995**

(87) International publication number:
WO 95/018608 (13.07.1995 Gazette 1995/30)

(54) **METHOD OF TREATING DISORDERS OF THE ANIMAL OR HUMAN BODY BY ADMINISTERING AMINO ACIDS**

VERFAHREN ZUR BEHANDLUNG VON STOEHRUNGEN DES MENSCHLICHEN ODER
TIERISCHEN KOERPERS DURCH VERABREICHUNG VON AMINOSAEUREN

PROCEDE DE TRAITEMENT DE TROUBLES CHEZ L'ANIMAL OU CHEZ L'HOMME PAR
ADMINISTRATION D'ACIDES AMINES

(84) Designated Contracting States:
BE CH DE ES FR GB LI NL

(74) Representative: **van Westenbrugge, André et al**
Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague (NL)

(30) Priority: **11.01.1994 EP 94200042**

(43) Date of publication of application:
23.10.1996 Bulletin 1996/43

(56) References cited:
EP-A- 0 329 879 EP-A- 0 401 056
EP-A- 0 441 119 EP-A- 0 494 848
WO-A-87/01589 WO-A-91/07188
WO-A-92/04895 DE-U- 9 110 794

(73) Proprietor: **N.V. Nutricia**
NL-2712 HM Zoetermeer (NL)

(72) Inventors:
• **VAN LEEUWEN, Paulus, Aloisius, Marie**
NL-1187 RB Amstelveen (NL)
• **HOUDIJK, Alexander, Petrus, Jacobus**
NL-1181 RS Amstelveen (NL)

- **PATENT ABSTRACTS OF JAPAN vol. 17, no. 689**
(C-1143) 16 December 1993 & JP,A,05 229 940
(AJINOMOTO CO INC) 7 September 1993
- **DATABASE WPI Week 8640, Derwent**
Publications Ltd., London, GB; AN 86-260176 &
JP,A,61 186 320 (MORISHITA PHARM KK) 20
August 1986

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 738 146 B1

Description

[0001] The invention relates to a method of treating disorders of the animal or human body which require increasing blood flow to intestinal organs as well as to a method of treating disorders which can be treated by administering arginine.

[0002] The present invention relates in particular to the use of glutamine in the diseased state where there is a decreased blood flow to the liver or where there are low arginine plasma levels.

[0003] The splanchnic bed consists of several organs all of which drain into the portal vein. A liver receives its blood supply from both the portal vein and the hepatic arteria. 70-80% of the blood flow to the liver is received by the portal vein and therefore most of the nutrients and oxygen is taken out of the blood coming from the portal vein and is thus insufficient during a decrease in blood flow. Glutamine is capable of increasing blood flow through the liver by increasing splanchnic blood flow.

[0004] During periods of decreased blood flow (systemic inflammation, hypovolemia, cardiac shock, decreased peripheral resistance), blood flow to the liver is lower.

[0005] After normalisation of the blood flow, the liver passes into the stage of reperfusion damage which compromises blood flow in the liver, which further deteriorates liver function. Blood flow then is mostly maintained in the liver by increased nitric oxide (NO) production. Arginine is the substrate for NO. When there is an increased demand for NO, there may not be sufficient arginine as a substrate, or there may be an increased demand for arginine.

[0006] Those diseased states are during low arginine level e.g. endotoxemia, systemic inflammation, high arginase content in plasma, bacteremia, obstructive jaundice, other types of jaundice, liver transplantation, liver resection, inflammatory bowel disease, transplantation in general, increased cytokine production, steatosis of the liver.

[0007] Thus the invention is specifically directed at the use of glutamine or a glutamine equivalent for preparing a medicinal or nutritional composition for the treatment of diseased states where there is a decreased blood flow to the liver. Glutamine or its equivalent is used according to the invention at a level of 0.2-4 g per kg body weight per day.

[0008] A glutamine equivalent is understood to be a substance which can be converted to glutamine, such as a glutamine dipeptide or a 2-acylaminoglutaric acid monoamide. The glutamine or glutamine equivalent in the medicinal or nutritional composition may be supplemented by arginine or an arginine equivalent, e.g. to an amount of 0-50%, especially 1-25% of the combined amounts of glutamine and arginine and their equivalents. The medicinal or nutritional composition contains an amount of glutamine or glutamine equivalent such as to provide a daily glutamine dosage of 0.2-4 g/kg body weight. This means that glutamine or its equivalent is administered in amount of e.g. 10-200 g/day for a subject having a body weight of 50 kg, or 20-400 g/day for a subject having a body weight of 100 kg. Below, the levels to be used are given on the basis of an assumed average body weight of 75 kg, but adaptations can be made as necessary.

[0009] The medicinal and nutritional compositions according to the invention are preferably formulated as enteral compositions. The composition may be a complete artificial food, i.e. which does not require additional food, or a food supplement. The further components of a complete food are preferably based on the recommended daily allowances (RDA) as generally accepted; the protein fraction may be based on a protein source rich in glutamine, or its hydrolysates. A supplement may be a glutamine concentrate, e.g. obtained by hydrolysis of raw materials rich in glutamine, such as wheat protein. The enteral food may then be obtained by mixing, before use, of the concentrate with a basic food, e.g. according to the RDA. The composition preferably is a liquid composition for oral or catheterised administration. Preferably the composition is a nutritional composition which also contains carbohydrates, proteins, lipids, and especially fibres, in amounts that are sufficient for meeting a minimum daily nutritional requirement.

[0010] The invention also concerns novel nutritional compositions suitable for improving liver function, containing, as a daily dosage unit, 12-300 g of glutamine or a glutamine equivalent, together with an amount of carbohydrates, proteins, lipids, vitamins, minerals and vegetable fibres, which is sufficient for meeting a minimum daily nutritional requirement. The nutritional composition preferably contains, as a daily dosage unit, especially 15-300, more preferably 16-150, more in particular 30-100 g of glutamine or a glutamine equivalent. The amount of glutamine or equivalent thereof can also be given with reference to the total weight of the composition. In case of liquid compositions, which are preferred, the amount of glutamine is in particular from 7 to 150 g/l, especially from 15 to 150, more in particular 25 to 75 g/l.

[0011] Especially preferred are nutritional compositions containing at least 10 g of vegetable fibres and/or 5 g of inulin (indigestible carbohydrate) on a daily basis. Fibres and/or inulin may be used in amounts up to e.g. 90 g per day.

[0012] Where the amount of glutamine is too high to be able to be homogeneously mixed with the other components, it is advantageous to prepare a nutritional composition, wherein at least a part (e.g. $\geq 75\%$) of the glutamine is in a package form separate of the major part (e.g. $\geq 75\%$) of the composition. The separate packages can then be combined before use. In such a way, stability problems can be overcome.

[0013] The invention also provides a method of treating disorders of the animal or human body which can be treated by administering arginine, such as reduction of blood cholesterol levels (cf. US-A-5,157,022) or treatment of vascular

resistance disorders (cf. US-A-5,217,997), comprising administering an effective amount of glutamine or a glutamine equivalent. An effective amount preferably is an amount which is greater than the glutamine level in a normal animal or human diet as indicated above, e.g. between 0.2 and 4 g/kg b.w. day.

[0014] The invention is also concerned with the use of glutamine for the treatment of adverse effects associated with impaired reticulo-endothelial system (RES) function and specifically for the treatment of adverse effects associated with impaired RES function resulting from insults to the liver. The RES, also called the mononuclear phagocyte system (MPS) consists of tissue macrophages and blood monocytes. The major sites of RES intravascular activity are located in the liver and spleen, which comprise about 85% and 10%, respectively, of total body activity. The Kupffer cells and the endothelial cells of the liver are capable of scavenging antigens and endotoxins from the portal vein and the systemic circulation. Kupffer cells reside in the liver for a few weeks and are then replaced by circulating monocytes that subsequently differentiate into new Kupffer cells. In response to injury or liver resection, Kupffer cells can divide and proliferate locally to restore the hepatic function. It was found that the administration of relatively high levels of glutamine has a beneficial effect on the restoration of this type of liver functioning.

[0015] The combined use of glutamine and alanine for the treatment of alcohol intoxication of the liver is described in EP-A-0,329,879. However, this reference does not contain any indication that glutamine, especially glutamine alone, could be useful in treating diseased states that are associated with a decreased liver blood flow. Moreover the dosages suggested in EP-A-0,329,879 are in the order of 1-20 g per person per day, which is well below the dosages contemplated according to the present invention.

[0016] Most other suggested uses for glutamine as a medicament relate to the use in parenteral administrations, such as in connection with improving nitrogen balance, prevention of gut mucosal atrophy and subsequent bacterial translocation and stimulation of lymphocyte responsiveness; these functions do not indicate a utility for diseased states in connection with a decreased hepatic blood flow as according to the present invention.

Example 1

Materials and methods

[0017] Male Fischer 344 rats (n=24, 240-260 g, Harlan CPB, Zeist, NL) were maintained in accordance with the recommendations of the Guide for the Care of Laboratory Animals. After acclimatisation to the laboratory environment for 5 days, rats were housed individually and subjected to a 12 hrs. light/dark cycle at controlled environmental conditions. Prior to the experiment, a three days period was taken for nutritional adaptation to the pulverized standard rat chow (SRM-A, Hope Farms, Woerden, NL). Rats were then randomized to receive either a glutamine supplemented enteral diet (n=12) or an isocaloric, isonitrogenous control diet (n=12) for 14 days. The glutamine enriched diet was prepared by adding 12.5 % (w/w) L-glutamine powder to the pulverized standard rat chow. In the control diet, glutamine was replaced by the following aminoacids: asparagine (ASN, 3.3 %), serine (SER, 2.4 %), glycine (GLY, 3.9 %), proline (PRO, 2.6 %) and alanine (ALA, 2.0 %) to balance the nitrogen and caloric content of the glutamine supplemented diet. These non-essential aminoacids have been used in studies investigating several effects of glutamine metabolism; alanine was chosen to compensate for glutamine-induced intestinal alanine synthesis. Food intake and urinary output were recorded daily. Body weights were recorded on day 1, 5, 10 and 14. Samples were taken from the 24 hrs urine collections of days 1, 4, 7, 9, 11 and 14 nitrate determination. Blood flow measurements were performed during the morning of the fifteenth day; until that time, the rats were allowed their respective diets.

Hemodynamic measurements: Blood flow measurements were performed using the radiolabeled microsphere method as previously described (refs 1, 2). Briefly, on the morning of the fifteenth day animals were anesthetized using Ketamine HCl (50 mgkg⁻¹ i.p.) and placed in the supine position on a heating pad that maintained rectal temperature at 37°C. The trachea was intubated with a small piece of polyethylene tubing (PE-240, Fischer, Scientific, Springfield, N.Y., USA) to facilitate breathing. The right carotid artery and left femoral artery were cannulated using PE-50 tubing. Both catheters were connected to P23Db Statham pressure transducers to monitor placement of the carotid catheter into the left cardiac ventricle and to measure femoral artery blood pressure. Following these procedures, rats were allowed to stabilize for 20 minutes prior to microsphere injection.

Microspheres labeled with ⁴⁶Sc were suspended in 0.9 % NaCl with two drops of 0.05 % Tween-80. The microspheres were ultrasonicated and thoroughly mixed with a Vortex shaker prior to injection. The microsphere vial was placed in a specially adjusted small electromagnetic motor and a magnetic stirring rod in the vial assured continuous mixing of the microspheres during the injection. A 0.7 ml suspension containing 1.0 - 1.5 x 10⁵ microspheres was injected in the left ventricle over a 20 sec. period, and a reference blood sample was obtained from the femoral artery by a calibrated roller pump starting 5 sec. before microsphere injection at a rate of 0.50 ml.min⁻¹ for 90 seconds. Following the microsphere procedures, arterial blood was drawn from the aorta for determinations of plasma levels of glutamine, urea, creatinine, ammonia and glucagon. The animals were killed by an intra-arterial injection of pentobarbital sodium (100 mg kg⁻¹). After verification of the position of the left ventricular catheter and inspection of the interventricular septum,

organs were removed for measurements of radioactivity. Mesenteric fat and superfluous tissue was removed from the organs. Blood flow to the skin and muscle tissue was not measured. The gastrointestinal organs were emptied of their contents. From stomach to colon the presence of digested food substances was confirmed in all the animals investigated. Organs were wrapped in tissue paper and dried under pressure of a 200 g for 15 sec. to remove superfluous extracellular fluid (ref. 3). The organs were weighed and placed in counting vials. The larger organs were divided in portions of ± 2 g to assure good geometric distribution within the counting vials. Radioactivity was counted in a well type gamma counter (Type LKB-1280, Ultrogamma, Wallac, Turku, Finland). Count rates were corrected for natural background and counter dead time. Organ blood flows (F) and cardiac output were computed according to the 'reference organ' technique (ref. 2). Organ blood flow was calculated using the equation: $F = F_a (Q_o/Q_a)$, where F_a is reference flow, Q_o is the count rate in the organ and Q_a is the count rate in the reference blood sample. Reference flow was computed from the weight of blood in the sampling syringe and the duration of withdrawal, assuming a whole blood density of 1.069 g/ml. Portal venous flow was computed as the sum of the arterial flows through the splanchnic organs i.e. the stomach, pancreas, spleen, small intestine and colon. Hepatic arterial and portal flows were summed to obtain total liver flow. Cardiac output (CO) was calculated according to the equation: $CO = F_a (Q_{tot}/Q_a)$, where Q_{tot} is the total injected radioactivity determined by subtracting residual activity in the catheter and injection vial from the initially recorded activity. Q_a is the activity in the reference sample and F_a is reference flow.

Blood sampling and chemical blood analysis: Prior to microsphere injection, blood samples (50 μ l) were drawn from the femoral artery catheter for hematocrit and pH determination. To determine acid base balance, pH was measured as part of a blood gas analysis using a commercial blood gas analyzer (ABL 330, Radiometer, Copenhagen, DK). Hematocrit was measured using a microhematocrit reader. For glutamine determination, heparinized arterial blood samples (1 ml) were immediately placed on ice and centrifuged at 1500 g for 10 minutes at 4°C. (Sorval GLC 2 centrifuge, Sorvall Operations, DuPont, Newton, CN, US). Plasma was deproteinized with sulfosalicylic acid (4 mg 100 μ l⁻¹) and put in liquid nitrogen. Samples were stored at -70°C prior to analysis. Glutamine levels were determined by high performance liquid chromatography and pre-column derivatization with ortho-phthalaldehyde reagent containing 3-mercaptopropionic acid as recently described (ref. 4). Aliquots of the arterial plasma samples were used for urea, creatinine and ammonia determination by standard enzymatic methods.

Glucagon assay: Two radioimmunoassays were performed to determine plasma glucagon levels in eight rats of each dietary group as described earlier (ref. 5). One assay determined total glucagon immunoreactivity, using a N-terminally reacting antiserum R59, the other detected pancreatic glucagon, using a specific C-terminally reacting antiserum, RCS5. Enteroglucagon was obtained by subtracting the levels of pancreatic glucagon from total glucagon levels. Changes of 10 pmol/L could be detected with 95 percent confidence.

Nitrate assay: Nitrate (NO_3^-) was determined in samples taken from both diets and in samples from 24 hours urine collections. Samples taken from the control and glutamine supplemented diet were diluted 1:5 (w/v) with 80 % ethanol, incubated in a shaking water bath for 3 hr at 50 °C and centrifuged for 5 min. at 10,000 g and 4 °C, the supernatant was decanted and analyzed for nitrate content. Samples taken from the 24 hours urine collections of day 1, 4, 7, 9, 11 and 14 were also assayed for nitrate content. Nitrate was determined after enzymatic conversion of NO_3^- to nitrite with nitrate reductase from *Aspergillus* (Boehringer, Mannheim, DE). The nitrite formed was quantitated by the colorimetric reaction according to Griess (ref. 6). For determining NO_3^- levels in urine samples, urine was diluted 20 times with bidistilled water. To 0.1 ml of diluted urine 0.5 ml phosphate buffer (pH 7.5, 35 mM), 0.05 ml nitrate reductase 1mu/L and 0.05 ml NADPH (1.8 mM) were added and the reaction mixture was incubated at room temperature for 2 hours. Excess NADPH, which interferes with the Griess reaction, was then oxidized by adding 0.05 ml phenazine methosulfate (8 nM). For the Griess reaction, 0.25 ml sulfanil reagents (0.1 M sulfanilamide in 1.5 M phosphoric acid) and 0.25 ml N-(1-naphtyl)ethylenediamine (8 mM) were added. After 15 minutes at room temperature, samples were measured at 540 nm in a Vitalab 20 colorimeter (Vital Scientific, NL). The assay was standardized with potassium nitrate solutions ranging from 20 to 200 μ mol/L. The detection limit of the assay was 0.4 μ mol/L, and the recovery of known amounts of nitrate standards added to control urine samples was 99.7 ± 3.1 % (mean $\pm$ SD).

Statistical analysis: All results are means $\pm$ SEM. Significant differences between means were determined using Student's T test (two-tailed). A p value <0.05 was considered statistically significant.

Results

[0018] General: No significant differences in body weights were found between the groups on any of the recorded days, and growth rates were comparable to rats of the same age that were fed normal rat chow. The mean daily food intake (18.6 ± 0.3 g) and mean daily caloric intake (84.7 ± 0.8 kcal) of control rats compared to glutamine supplemented rats (19.0 ± 0.3 g and 86.3 ± 1.1 kcal per day, respectively) were not significantly different. No differences were observed in mean daily urinary output between control and glutamine group (18.0 ± 0.6 and 18.3 ± 0.6 ml per day). Glutamine plasma levels were significantly higher in glutamine supplemented rats (788 ± 23 μ mol/l) compared to control rats (668 ± 25 μ mol/l) (p<0.005). No significant differences were found in hematocrit, arterial blood pH and pCO₂ values and

plasma levels of creatinine and urea between glutamine supplemented and control rats.

Hemodynamic data: Reliability of microsphere injections was evaluated using the criteria of Hernandez et al. (ref. 3). Differences in total counts per minute for both kidneys was < 6 %, evidencing good microsphere mixing and distribution. None of the animals had high lung counts indicating an intact interventricular septum. Differences between blood pressure recordings before and after microsphere injection never exceeded a level of 6 mmHg. No differences between the groups were noted for any of the measured (cardiac output, mean arterial pressure and heart rate), nor for calculated systemic hemodynamic parameters (total peripheral resistance, stroke volume and cardiac index). No differences were noted in organ wet weights between the animals fed the control and those receiving the glutamine supplemented diet. In the glutamine enriched group, significantly higher blood flows were measured in the stomach, the pancreas, the small intestine and colon either expressed as ml.min⁻¹ or as ml.min⁻¹g⁻¹ wet weight. In addition, calculated splanchnic blood flow (stomach + pancreas + spleen + small intestine + colon) and total hepatic blood flow (splanchnic + hepatic arterial) were calculated and were significantly higher in rats fed the glutamine enriched diet (Table 1). In the animals fed the glutamine enriched diet, significantly higher percentages of cardiac output were distributed to the stomach (+ 66%), pancreas (+ 42%), small intestine (+ 56%) and colon (+ 67%). As a result, in glutamine supplemented animals, significantly higher percentages of cardiac output were distributed to the splanchnic organs as a whole (control vs glutamine: 14.95 ± 1.41 vs 22.24 ± 1.17; p<0.0005) and to the liver (sum of splanchnic and hepatic arterial flow; control vs glutamine: 18.00 ± 1.47 vs 25.47 ± 1.09 = + 42%; p<0.001).

Table 1

organ or tissue	organ flow, ml/min		flow, ml/min.g	
	control	glutamine	control	glutamine
brain	0.59 ± .05	0.52 ± .06	0.45 ± .05	0.45 ± .04
heart	3.83 ± .53	3.10 ± .41	4.49 ± .66	4.01 ± .49
lungs	0.85 ± .19	0.66 ± .16	0.79 ± .22	0.63 ± .16
diaphragm	0.27 ± .05	0.27 ± .01	0.21 ± .02	0.23 ± .01
liver (A. hep.)	2.09 ± .21	2.18 ± .30	0.34 ± .05	0.33 ± .02
stomach	0.57 ± .06	0.86 ± .07	0.44 ± .06	0.70 ± .06
spleen	1.01 ± .27	1.01 ± .13	1.48 ± .16	1.61 ± .08
pancreas	0.77 ± .06	1.04 ± .10	0.92 ± .14	1.31 ± .15
small intestine	7.02 ± .63	9.23 ± .43	2.37 ± .18	3.47 ± .29
colon	1.86 ± .16	2.89 ± .19	1.13 ± .07	1.81 ± .23
kidneys	11.9 ± 1.0	11.2 ± 0.9	5.55 ± .41	5.16 ± .40
splanchnic	11.5 ± 1.1	15.0 ± 0.7		
total hepatic	13.6 ± 1.1	17.3 ± 0.6		

Glucagon measurements: No differences were observed in plasma levels of pancreatic glucagon and total glucagon between the glutamine supplemented and control dietary group.

Nitrate measurements: Both the control and glutamine enriched diets were analyzed for NO₃⁻ content using four samples of each of the two diets. Mean nitrate content was 1.71 ± 0.08 and 1.68 ± 0.01 µmol/g for the control and glutamine enriched diet, respectively (n.s.). On days 4, 7, 9 and 11 NO₃⁻ production was slightly higher in rats fed the glutamine enriched diet compared to control animals; however, this difference did not reach statistical significance. Mean daily NO₃⁻ production was calculated and showed no significant differences between the glutamine supplemented and con-

trol group.

Discussion

[0019] The present example demonstrates that, compared to an isonitrogenous, isocaloric control diet, a glutamine enriched enteral diet increases splanchnic blood flow by increasing blood flow to the stomach, small intestine, colon and pancreas, and increases total hepatic blood flow by about 27%. Growth rates and mean daily food and calory intake were similar for both groups, indicating that the diets were nutritionally comparable. The calculated mean enteral daily intake of glutamine approximated 2.4 g., which was higher than the daily amount administered by a 2 % glutamine enriched parenteral nutrition (1.0 - 1.8 g.), used in several studies (refs 7, 8). However, the animals fed the 12.5% glutamine enriched diet, showed no signs of metabolic derangements due to increased levels of ammonia and urea, the potentially toxic endproducts of glutamine metabolism. In the present study, the composition of the glutamine enriched and control diet only differed in their relative aminoacid contents. Therefore, changes in splanchnic blood flow were not due to differences in fat or carbohydrate content. The supplemented glutamine in the experimental diet was replaced by ASN, SER, GLY, PRO and ALA in the control diet. These five non-essential aminoacids have been reported not to influence local jejunal blood flow at high postprandial luminal concentrations (ref. 9). Thus, the increase in splanchnic blood flow in rats fed the glutamine enriched diet can only be attributed to glutamine supplementation. The increases in blood flows to the gastrointestinal organs in the animals fed the glutamine enriched diet occurred in the absence of any changes in cardiac output resulting in greater percentages of cardiac output distributed to each of these organs compared to rats fed the control diet. This indicates that the increased blood flows to the splanchnic organs in the glutamine fed group is based on local vasodilatory responses. No differences in arterial pancreatic glucagon plasma levels were noted between the rats fed the control and glutamine enriched diet, indicating that the glutamine induced increases in splanchnic blood flow upon enteral administration were not mediated by glucagon. The mean daily NO_3^- production was not different between the control and glutamine group, suggesting that NO production did not play a role in the splanchnic vasodilatory response to glutamine. In conclusion, the present example shows that compared to a balanced control diet, a glutamine enriched enteral nutrition increased splanchnic blood flow, and thus total hepatic blood flow in the rat. The increases in organ blood flow were not mediated by an increased production of pancreatic glucagon or nitric oxide as determined by urinary nitrate excretion. These findings are of clinical importance.

Example 2

[0020] This example provides evidence that glutamine-supplemented enteral nutrition increases renal arginine production by providing increased levels of circulating citrulline to the kidneys. Thus glutamine enriched enteral nutrition in the rat significantly increases arterial arginine plasma levels by increasing renal arginine production.

Materials and methods

[0021] *General:* Rats were maintained and fed as in Example 1.

Kidney blood flow measurement and blood sampling: Kidney blood flow measurements were performed using the radiolabeled microsphere method as described in Example 1. Following blood flow measurement the abdomen was opened and the left renal vein was cannulated using a 12 gauge needle attached to a heparinized syringe. The renal vein was clipped at its entrance into the caval vein and a blood sample (1 ml) was drawn. An additional blood sample was drawn from the abdominal aorta. Rats were killed by an overdose of sodium pentobarbital (100 mg kg^{-1}). After verification of the position of the left ventricular catheter the kidneys were removed, weighed and placed in counting vials. Radioactivity and organ blood flow measurements were performed as in Example 1.

Aminoacid and chemical blood analysis: Blood samples were immediately placed on ice. After centrifugation at 3000 rpm for 10 min. at 4°C , aliquots of plasma were pipetted in cryo-vials containing crystallized sulfosalicylic acid ($4 \text{ mg}/100 \mu\text{l}$), immediately Vortex mixed and put in liquid nitrogen. Samples were stored at -70°C until aminoacid determination. Aminoacids involved in arginine synthesis were determined in plasma using HPLC. Aliquots of the arterial plasma samples were used for ammonia and urea determination by standard enzymatic methods.

Calculations: Net aminoacid fluxes over the kidneys were computed by the following equation: Net kidney flux ($\text{nmol}\cdot\text{ml}^{-1}\cdot\text{min}^{-1}$) = $([A] - [\text{RV}]) \times F$, where $[A]$ represents the arterial plasma aminoacid concentration, $[\text{RV}]$ the plasma aminoacid concentration in the renal vein and F plasma flow through both kidneys (the sum of the left and right kidney plasma flows). According to this method a minus sign indicates release. Net extraction rate (E_{net}) was calculated as follows: $[A] - [\text{RV}]/[A]$.

Statistical analysis:

[0022] All results are means $\pm$ SEM. Significant differences between means were determined using Student's T test. A p value < 0.05 was considered statistically significant.

Results

[0023] *General:* There were no statistical significant differences in body weights between the rats in the glutamine supplemented and control group on any of the recorded days (cf. Example 1). Total kidney weights (sum of left and right kidneys) were not different between the control and glutamine group (2.17 ± 0.03 and 2.19 ± 0.07 g resp.). No significant differences in haematocrit, arterial pH and arterial plasma concentrations of ammonia and urea was found between rats fed the glutamine supplemented and control diet.

Kidney aminoacid handling: Table 2 shows the results of arterial and renal venous plasma aminoacid determinations, A-RV differences, net kidney flux and net extraction calculations. There was no difference in total kidney plasma flow between the glutamine and control group (5.57 ± 0.27 and 5.71 ± 0.28 mlmin⁻¹ resp.). The animals fed the glutamine enriched diet showed significantly higher mean arterial plasma concentrations of glutamine (17 %), arginine (31 %) and citrulline (30 %). Significantly higher renal venous plasma concentrations of glutamine (6 %), citrulline (22 %) and arginine (31 %) were detected in the glutamine enriched group. Flux calculations showed a significantly higher uptake of circulating glutamine (306 %), aspartate (318 %) and citrulline (40 %) by the kidneys of rats fed the glutamine enriched diet. The release of arginine by the kidney was significantly higher (38 %) in the glutamine fed rats. In the glutamine fed animals net extraction rates of the kidneys for glutamine and aspartate significantly increased. No changes in net extraction rates were observed for glutamate, citrulline, arginine and omithine. A highly significant correlation between citrulline uptake and arginine release by the kidneys was found in both the control group and glutamine group ($r=0.84$; $p<0.0001$ and $r=0.83$; $p<0.0001$ resp.).

Table 2. Glutamine enriched diet: the effect on kidney aminoacid handling

	A		RV		A-RV		Kidney flux		Enet kidney	
	Control	Glutamine	Control	Glutamine	Control	Glutamine	Control	Glutamine	Control	Glutamine
GLN	668.5 ± 25.1	788.4 ± 22.6 [#]	646.5 ± 20.0	688.1 ± 29.0	23.8 ± 22.0	99.3 ± 14.1 ^{**}	136.0 ± 139.1	553.2 ± 89.1 [*]	0.03 ± 0.03	0.13 ± 0.02 ^{**}
GLU	58.3 ± 6.1	67.8 ± 6.6	52.9 ± 3.2	59.7 ± 3.2	4.7 ± 4.8	12.2 ± 5.3	28.9 ± 30.1	65.9 ± 29.0	0.03 ± 0.07	0.12 ± 0.06
ASP	5.9 ± 0.5	7.2 ± 1.1	3.7 ± 0.9	2.8 ± 0.6	1.3 ± 0.7	4.4 ± 1.2 [*]	5.8 ± 2.8	24.3 ± 6.4 [*]	0.2 ± 0.1	0.6 ± 0.1 [*]
ARG	86.8 ± 4.4	113.7 ± 4.8 [!]	110.1 ± 3.6	145 ± 5.6 ^{!!}	-23.9 ± 3.1	-32.4 ± 3.7 [*]	-131.4 ± 18.0	-181.6 ± 18.2 [*]	-0.29 ± 0.04	-0.29 ± 0.03
CIT	48.1 ± 1.3	62.7 ± 2.1 ^{!!}	25.5 ± 1.5	30.3 ± 1.3 ^{**}	22.6 ± 2.5	32.4 ± 2.3 ^{**}	128.9 ± 14.8	180.7 ± 16.3 [*]	0.47 ± 0.04	0.51 ± 0.03
ORN	30.0 ± 1.9	33.4 ± 1.9	31.0 ± 1.4	33.7 ± 1.8	-1.0 ± 1.4	-0.3 ± 0.9	-5.7 ± 8.1	-1.7 ± 5.0	-0.03 ± 0.05	-0.01 ± 0.03

Data are expressed in nmol ml^{-1} (A, RV and A-RV) and nmol min^{-1} (Kidney flux) and as means ± SEM. A and RV represent arterial and renal venous plasma aminoacid concentrations. Enet kidney is neto extraction rate of aminoacids by the kidney. Numbre of observations is 12 in each group. Statistical analysis by Students T test. Significances are indicated as follows: ^{*} $p < 0.05$, ^{**} $p < 0.01$, [#] $p < 0.005$, [!] $p < 0.001$, ^{!!} $p < 0.0005$ and ^{'''} $p < 0.0001$.

References

[0024]

1. Van Leeuwen, P.A.M., J.R. Bading, N.A. Vydellingum, R.N. Younes, P. de Rooij, and M. Brennan. *J. Appl. Physiol.* 71(5): 1674-1678, 1991.
2. Malik, A.R., J.E. Kaplan, and T.M. Saba. *J. Appl. Physiol.* 40: 472-475, 1976.
3. Hernandez, L.A., P.R. Kvietys, and D.N. Granger. *Am. J. Physiol.* 251 (Gastrointest. Liver Physiol. 14): G117-G123, 1986.
4. Teerlink, T., M.W.T. Hennekes, P.A.M. van Leeuwen, and A.P.J. Houdijk. *Clinica Chimica Acta* 218: 159-168, 1993.
5. Thomson, J.P.S., and S.R. Bloom. *Clin. Sci. Mol. Med.* 51: 177-183, 1976.
6. Green, L.C., D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum. *Anal. Biochem.* 126: 131-138, 1982.
7. Li, S.L., M.S. Nussbaum, D.W. McFadden, F-S. Zhang, R.J. LaFrance, R. Dayal, and J. Fischer. *J. Surg. Res.* 48: 421-426, 1990.
8. Yoshida, S., M.J. Leskiw, M.D. Schlatter, K.T. Bush, R.G. Nagele, S. Lanza-Jacoby, and T.P. Stein. *Am. J. Physiol.* 263: (Endocrinol. Metab. 26): E368-E373, 1992.
9. Chou, C.C., P. Kvietys, J. Post, and S.P. Sit. *Am. J. Physiol.* 235(6): H677-H682, 1978.

Claims

1. Use of glutamine or a glutamine equivalent for preparing a medicinal or nutritional composition to provide a daily glutamine dosage of 0.2-4 g per kg body weight, for the treatment of diseased states where there is a decreased blood flow to the liver.
2. Use according to claim 1, wherein the medicinal or nutritional composition also contains arginine or an arginine equivalent.
3. Use according to claim 1 or 2, wherein the nutritional composition also contains carbohydrates, proteins, lipids, and especially fibres.
4. Use according to any one of claims 1-3, wherein the nutritional composition also contains at least 10 g of vegetable fibre and/or 5 g of inulin per daily dosage unit.
5. Nutritional composition suitable for improving liver function, containing, as a daily dosage unit, 12-300 g of glutamine or a glutamine equivalent, together with an amount of carbohydrates, proteins, lipids, vitamins and minerals, which is sufficient for meeting a minimum daily nutritional requirement, and at least 10 g of vegetable fibres and/or 5 g of inulin.
6. Nutritional composition according to claim 5, which contains, as a daily dosage unit, 16-150 g of glutamine or a glutamine equivalent.
7. Nutritional composition according to claim 5 or 6, wherein the composition is a liquid.
8. Nutritional composition according to one of claims 5-7, which contains at least a part of the glutamine in a package form separate from the major part of the composition.

Patentansprüche

1. Verwendung von Glutamin oder eines Glutamin-Äquivalents zur Herstellung einer medizinischen Zusammensetzung oder einer Nahrungsmittel-Zusammensetzung zur Bereitstellung einer täglichen Glutamindosierung von 0,2 - 4 g/kg Körpergewicht für die Behandlung von Krankheitsbildern, bei denen ein verringerter Blutfluss zur Leber besteht.
2. Verwendung nach Anspruch 1, wobei die medizinische oder Nahrungsmittel-Zusammensetzung auch Arginin oder

ein Arginin-Äquivalent enthält.

3. Verwendung nach Anspruch 1 oder Anspruch 2, wobei die Nahrungsmittel-Zusammensetzung auch Kohlenhydrate, Proteine, Lipide und speziell Fasern enthält.
4. Verwendung nach einem der Ansprüche 1 - 3, wobei die Nahrungsmittel-Zusammensetzung auch mindestens 10 g pflanzliche Fasern und/oder 5 g Inulin pro Tagesdosis-Einheit enthält.
5. Nahrungsmittel-Zusammensetzung, die zur Verbesserung der Leberfunktion geeignet ist und die als Tagesdosis-Einheit 12 - 300 g Glutamin oder Glutamin-Äquivalent zusammen mit einer Menge an Kohlenhydraten, Proteinen, Lipiden, Vitaminen und Mineralien, die ausreicht, um den täglichen Nahrungsmindestbedarf zu decken, und mindestens 10 g pflanzliche Fasern und/oder 5 g Inulin enthält.
6. Nahrungsmittel-Zusammensetzung nach Anspruch 5, die als Tagesdosis-Einheit 16 - 150 g Glutamin oder eines Glutamin-Äquivalents enthält.
7. Nahrungsmittel-Zusammensetzung nach Anspruch 5 oder Anspruch 6, wobei die Zusammensetzung eine Flüssigkeit ist.
8. Nahrungsmittel-Zusammensetzung nach einem der Ansprüche 5 - 7, die mindestens einen Teil des Glutamins in einer Verpackungsform getrennt vom Hauptteil der Zusammensetzung enthält.

Revendications

1. Utilisation de glutamine ou d'un équivalent de la glutamine pour préparer une composition médicinale ou nutritionnelle pour fournir une dose de glutamine quotidienne de 0,2 à 4 g par kg de poids corporel, pour le traitement d'états malades où il y a un flux sanguin diminué vers le foie.
2. Utilisation, selon la revendication 1, dans laquelle la composition médicinale ou nutritionnelle contient également de l'arginine ou un équivalent de l'arginine.
3. Utilisation, selon la revendication 1 ou 2, dans laquelle la composition nutritionnelle contient également des glucides, des protéines, des lipides et particulièrement des fibres.
4. Utilisation, selon l'une quelconque des revendications 1 à 3, dans laquelle la composition nutritionnelle contient également au moins 10 g d'une fibre végétale et/ou 5 g d'inuline par unité de prise quotidienne.
5. Composition nutritionnelle convenable pour améliorer la fonction hépatique contenant, comme unité de prise quotidienne, de 12 à 300 g de glutamine ou d'un équivalent de la glutamine, avec une quantité de glucides, protéines, lipides, vitamines et minéraux qui est suffisante pour satisfaire les besoins nutritionnels journaliers minimum et au moins 10 g de fibres végétales et/ou 5 g d'inuline.
6. Composition nutritionnelle, selon la revendication 5, qui contient, comme unité de prise quotidienne, de 16 à 150 g de glutamine ou d'un équivalent de la glutamine.
7. Composition nutritionnelle, selon la revendication 5 ou 6, dans laquelle la composition est un liquide.
8. Composition nutritionnelle, selon l'une des revendications 5 à 7, qui contient au moins une partie de la glutamine dans un conditionnement séparé de la majeure partie de la composition.